Inhibition of Selective Adhesion Molecules in Treatment of Inflammatory Bowel Disease

REFERENCES

• Assche G, Emerging drugs to treat Crohn's disease. Expert Opin Emerging Drugs. 2007;12:49–59.
   PubMedGoogle Scholar
• Roda G, Sartini A, Zambon E, Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol. 2010;16:4264–4271.
   PubMed Web of Science ®Google Scholar
• Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:967–974.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Reyna TS, Martínez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15:5517–5524.
   PubMed Web of Science ®Google Scholar
• Wahli W. A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med. 2008;263:613–619.
   PubMed Web of Science ®Google Scholar
• Actis GC, Rosina F, Mackay IR. Inflammatory bowel disease: beyond the boundaries of the bowel. Expert Rev Gastroenterol Hepatol. 2011;5:401–410.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Chaki R, Mandal V, Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. Int Rev Immunol. 2010; 29:4–37
   PubMed Web of Science ®Google Scholar
• Raza A, Yousaf W, Giannella R, Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol. 2012;8:161–168.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Seidelin JB, Munck LK, Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15–28.
   PubMedGoogle Scholar
• Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:567–572.
   PubMed Web of Science ®Google Scholar
• Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995;9:866–873.
   PubMed Web of Science ®Google Scholar
• Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2005;77:129–140.
   PubMed Web of Science ®Google Scholar
• Vestweber D. Ligand-specificity of the selectins. J Cell Biochem. 1996;61:585–591.
   PubMedGoogle Scholar
• Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79:181–213.
   PubMed Web of Science ®Google Scholar
• Walzog B, Gaehtgens P. Adhesion molecules: the path to a new understanding of acute inflammation. News Physiol Sci. 2000;15:107–113.
   PubMedGoogle Scholar
• von Andrian UH, Hasslen SR, Nelson RD, A central role for microvillous receptor presentation in leukocyte adhesion under flow. Cell. 1995;82:989–999.
   PubMed Web of Science ®Google Scholar
• Buscher K, Riese SB, Shakibaei M, The transmembrane domains of L-selectin and CD44 regulate receptor cell surface positioning and leukocyte adhesion under flow. J Biol Chem. 2010;285:13490–13497.
   PubMedGoogle Scholar
• Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79:181–213.
   PubMed Web of Science ®Google Scholar
• Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859–873.
   PubMed Web of Science ®Google Scholar
• Laroux FS, Pavlick KP, Wolf RE, Dysregulation of intestinal mucosal immunity: implications in inflammatory bowel disease. News Physiol Sci. 2001;16:272–277.
   PubMedGoogle Scholar
• Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases, I: immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288(2):G169–G174.
   Google Scholar
• Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009;3:77–97.
   PubMedGoogle Scholar
• Akiyama SK. Integrins in cell adhesion and signaling. Hum Cell. 1996;9:181–186.
   PubMedGoogle Scholar
• Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3:pii: a004994
   PubMed Web of Science ®Google Scholar
• Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:239–258.
   PubMedGoogle Scholar
• Hughes PE, Diaz-Gonzalez F, Leong L, Breaking the integrin hinge: a defined structural constraint regulates integrin signaling. J Biol Chem. 1996;271:6571–6574.
   PubMed Web of Science ®Google Scholar
• Arnaout MA. Integrin structure: new twists and turns in dynamic cell adhesion. Immunol Rev. 2002;186:125–140.
   PubMedGoogle Scholar
• García AJ, Takagi J, Boettiger D. Two-stage activation for alpha5beta1 integrin binding to surface-adsorbed fibronectin. J Biol Chem. 1998;273:34710–34715.
   PubMed Web of Science ®Google Scholar
• Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 2009;9:836–50.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372–2382.
   PubMed Web of Science ®Google Scholar
• Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94:1722–1728.
   PubMed Web of Science ®Google Scholar
• Zabel BA, Agace WW, Campbell JJ, Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med. 1999;190:1241–1256.
   PubMed Web of Science ®Google Scholar
• Johansson-Lindbom B, Svensson M, Wurbel MA, Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med. 2003;198:963–969.
   PubMed Web of Science ®Google Scholar
• Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004;4:83–89.
   Google Scholar
• Mora JR, Bono MR, Manjunath N, Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003;424:88–93.
   PubMed Web of Science ®Google Scholar
• Bridges LC, Tani PH, Hanson KR, The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1. J Biol Chem. 2002;277:3784–3792.
   PubMed Web of Science ®Google Scholar
• Li Z, Calzada MJ, Sipes JM, Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol. 2002;157:509–519.
   PubMed Web of Science ®Google Scholar
• Yakubenko VP, Lobb RR, Plow EF, Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res. 2000;260:73–84.
   PubMedGoogle Scholar
• Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007;7:467–477.
   PubMed Web of Science ®Google Scholar
• Mandell KJ, Babbin BA, Nusrat A, Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity. J Biol Chem. 2005;280:11665–11674.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Hardt K, Hatting M, Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. Immunology. 2009;128:196–205.
   PubMedGoogle Scholar
• Saunders KE, Shen Z, Dewhirst FE, Novel intestinal Helicobacter species isolated from cotton-top tamarins (Saguinus oedipus) with chronic colitis. J Clin Microbiol. 1999;37:146–151.
   PubMedGoogle Scholar
• Podolsky DK, Lobb R, King N, Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92:372–380.
   PubMed Web of Science ®Google Scholar
• Hamamoto N, Maemura K, Hirata I, Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol. 1999;117:462–468.
   PubMed Web of Science ®Google Scholar
• McNamee EN, Wermers JD, Masterson JC, Novel model of TH2-polarized chronic ileitis: the SAMP1 mouse. Inflamm Bowel Dis. 2010;16:743–752.
   PubMedGoogle Scholar
• Rivera-Nieves J, Olson T, Bamias G, L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol. 2005;174:2343–2352.
   PubMed Web of Science ®Google Scholar
• Matsuzaki K, Tsuzuki Y, Matsunaga H, In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol. 2005;140:22–31.
   PubMedGoogle Scholar
• Inoue T, Tsuzuki Y, Matsuzaki K, Blockade of PSGL-1 attenuates CD14+ monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol. 2005;77: 287–95.
   PubMedGoogle Scholar
• Siegmund B. Targeted therapies in inflammatory bowel disease. Dig Dis. 2009;27:465–469.
   PubMed Web of Science ®Google Scholar
• Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:967–974.
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI, A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268–274.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24–32.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912–1925.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–1683.
   PubMed Web of Science ®Google Scholar
• Dudley-Brown S, Nag A, Cullinan C, Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32:327–339.
   PubMedGoogle Scholar
• Feagan BG, Sandborn WJ, Hass S, Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007;102:2737–2746.
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J, Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13:2–11.
   PubMed Web of Science ®Google Scholar
• Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol. 2002;59:1930–1936.
   PubMedGoogle Scholar
• Yousry TA, Major EO, Ryschkewitsch C, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–933.
   PubMed Web of Science ®Google Scholar
• Tilg H, Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs. 2010;11:1295–1304.
   PubMedGoogle Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499–2507.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6: 1370–1377.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3:76–99.
   PubMed Web of Science ®Google Scholar
• Barish CF. Alicaforsen therapy in inflammatory bowel disease. Expert Opin Biol Ther. 2005;5:1387–1391.
   PubMed Web of Science ®Google Scholar
• Henry SP, Templin MV, Gillett N, Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol. 1999b;27: 95–100.
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease. Curr Opin Mol Ther. 1999;1:332–335.
   PubMedGoogle Scholar
• Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114:1133–1142.
   PubMed Web of Science ®Google Scholar
• van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646–1651.
   PubMed Web of Science ®Google Scholar
• van Deventer SJ, Wedel MK, Baker BF, A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415–1425.
   PubMed Web of Science ®Google Scholar
• Miner PB Jr, Geary RS, Matson J, Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1427–1434.
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, Goff J, Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51:30–36.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Ghosh S, Panes J, The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60:1068–1075.
   PubMed Web of Science ®Google Scholar
• Ten Hove T, The Olle F, Berkhout M, Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. J Leukoc Biol. 2004;75:1010–1015.
   PubMed Web of Science ®Google Scholar
• Stefanich EG, Danilenko DM, Wang H, A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011;162:1855–1870.
   PubMed Web of Science ®Google Scholar
• Rutgeerts Paul J, Fedorak Richard N, Hommes Daniel W, A Phase I study of rHuMab Beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology. 2011; 140:S1, 125
   Google Scholar
• Wurbel MA, Philippe JM, Nguyen C, The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol. 2000;30:262–271.
   PubMedGoogle Scholar
• Hosoe N, Miura S, Watanabe C, Demonstration of functional role of TECK/CCL25 in T lymphocyte–endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol. 2004;286:G458–G466.
   PubMed Web of Science ®Google Scholar
• Villablanca EJ, Cassani B, von Andrian UH, Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology. 2011;140:1776–1784.
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation. 2003;10:313–323.
   PubMed Web of Science ®Google Scholar
• Hart AL, Ng SC, Mann E, Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel Dis. 2010;16:1969–1977.
   PubMed Web of Science ®Google Scholar
• Miles A, Liaskou E, Eksteen B, CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1257–G1267.
   PubMed Web of Science ®Google Scholar
• Walters MJ, Wang Y, Lai N, Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010;335:61–69.
   PubMed Web of Science ®Google Scholar
• Bekker P, Keshav S, Johnson D, PROTECT-1 maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Advances in Inflammatory Bowel Diseases; Crohn's & Colitis Foundation's Clinical & Research Conference, Hollywood, FL. Inflammatory Bowel Diseases. 2009; 15: S2Abstract #P-0022
   Google Scholar
• Bekker P, Petryka R, Vanásk T, PROTECT-1, a prospective randomized oral therapy evaluation of CCX282-B (Trafficet-EN) in Crohn's disease trial. CCFA National Research and Clinical Conference, 6th Annual Advances in the Inflammatory Bowel Diseases, Dec. 6–9, Aventura, Florida. Inflammatory Bowel Diseases. 2007; 14:S11Abstract #P-003
   Google Scholar
• Takazoe M, Watanabe M, Kawaguchi T, S1066 oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;136:A–181.
   Google Scholar
• Lafrenie RM, Buckner CA, Bewick MA. Cell adhesion and cancer: is there a potential for therapeutic intervention? Expert Opin Ther Targets. 2007;11:727–731.
   PubMed Web of Science ®Google Scholar
• Podar K, Zimmerhackl A, Fulciniti M, The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011;155:438–448.
   Google Scholar
• Giovannoni G. Promising emerging therapies for multiple sclerosis. Neurol Clin. 2011;29:435–448.
   PubMedGoogle Scholar
• Polman CH, O'Connor PW, Havrdova E, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899–910.
   PubMed Web of Science ®Google Scholar
• Miller DH, Soon D, Fernando KT, MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–1401.
   PubMed Web of Science ®Google Scholar